Travere officer Reed plans $2.6M stock sale

An officer of Travere Therapeutics has filed a Rule 144 notice to sell 39,576 TVTX common shares valued at about $2.6 million.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) has a notice of proposed sale of common stock filed under Rule 144 for officer Elizabeth Reed. The notice covers 39,576 shares of Travere common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $2,603,705.04 and based on 94,261,082 shares outstanding as of September 15, 2026. The shares consist of 37,500 shares underlying stock options expected to be exercised for cash on September 15, 2026 and 2,076 shares from performance stock units with a date of May 4, 2026.

Key Figures

Shares proposed for sale: 39,576 shares Aggregate market value: $2,603,705.04 Shares underlying stock options: 37,500 shares +3 more

6 metrics

Shares proposed for sale 39,576 shares Common stock covered by Rule 144 notice for Elizabeth Reed

Aggregate market value $2,603,705.04 Value of 39,576 Travere common shares in the Form 144

Shares underlying stock options 37,500 shares Portion of proposed sale from exercise of stock options dated September 15, 2026

Shares from performance stock units 2,076 shares Portion of proposed sale from performance stock units dated May 4, 2026

Shares outstanding figure cited 94,261,082 shares Travere common shares cited as outstanding as of September 15, 2026

Sale method date reference September 15, 2026 Date tied to both the option exercise and main proposed sale

Key Terms

Rule 144, Exercise of Stock Options, Performance Stock Units, Executive Financial Services

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

Performance Stock Units financial

"Common | 05/04/2026 | Performance Stock Units | Issuer"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TVTX disclose about Elizabeth Reed?

The Form 144 reports that officer Elizabeth Reed plans to sell 39,576 shares of Travere Therapeutics common stock under Rule 144 through Morgan Stanley Smith Barney.

How many Travere Therapeutics (TVTX) shares are covered by this Rule 144 notice?

The notice covers 39,576 shares of Travere Therapeutics common stock, including 37,500 option shares and 2,076 performance stock unit shares.

What is the approximate market value of the TVTX shares in this Form 144?

The Form 144 states an aggregate market value of approximately $2,603,705.04 for the 39,576 shares of Travere Therapeutics common stock covered by the notice.

How are the TVTX shares in the Form 144 expected to be acquired before sale?

Of the 39,576 shares, 37,500 shares are tied to the exercise of stock options for cash dated September 15, 2026, and 2,076 shares relate to performance stock units dated May 4, 2026.

What share count does the Form 144 give for Travere Therapeutics (TVTX)?

The filing lists 94,261,082 shares of Travere Therapeutics common stock as the relevant outstanding share figure as of September 15, 2026.

On which market is Travere Therapeutics (TVTX) common stock referenced in the Form 144?

The Form 144 references Travere Therapeutics common stock as traded on the NASDAQ market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:44 PM Accepted by SEC EDGAR 09/15/2026 - 04:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001283303
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	ELIZABETH REED
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	39576	2603705.04	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			37500	09/15/2026	Cash
Common	05/04/2026	Performance Stock Units	Issuer			2076	05/04/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Elizabeth Reed
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)